PetVivo Engages Veteran Animal Health Executive Mike Eldred as Commercial and Operations Advisor

PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Mike Eldred as the Company’s Commercialization and Operations Advisor. Eldred's appointment as an Executive Director by the Company’s Board of Directors draws upon his 30 years of executive experience in animal health and the veterinary industry to ramp up its product development and sales efforts.

For the past 20 years, Eldred served as President of North American Operations for Dechra Pharmaceutical, a global specialist in veterinary pharmaceuticals. He built Dechra’s North American subsidiary from the ‘ground up’ to become one of the fastest growing companies in the industry, with more than 250 employees and revenue in excess of $400M. Eldred's experience and proven record of business achievement in the animal health market bring a valuable resource to PetVivo's Board, helping to achieve its business goals and drive the growing adoption of Spryng™.

Prior to Dechra, Eldred held senior positions in business development, sales, and operations at Virbac Corporation, Fort Dodge Animal Health, and Sanofi Animal Health. His extensive industry knowledge and network can help PetVivo identify key opportunities and challenges in promoting Spryng™, an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles that have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue.



Eldred commented, "I have closely followed PetVivo over the past few years, and I’m impressed with the company’s growth strategy and their innovative veterinary medical device - Spryng™, with OsteoCushion Technology. I’m excited to take a more active role at this pivotal time to help the company grow and expand the usage of Spryng in the US equine and companion animal markets."

Spryng has been shown to improve the medical outcomes of animals suffering from lameness and other joint related afflictions in multiple independent clinical studies. By mimicking and reinforcing natural joint cartilage, Spryng represents a highly effective, drug-free option for veterinarians looking for long-term solutions that can improve the mobility and quality of life for equines and companion animals.



PetVivo's strategic appointment of Mike Eldred as Commercialization and Operations Advisor comes at a critical juncture for the company, as it seeks to capitalize on the fast-growing US animal health market, which is projected to double to $11.3 billion by 2030. Eldred's leadership and industry expertise will be invaluable in driving PetVivo's product development and sales efforts, ultimately accelerating the adoption of Spryng™ in the US equine and companion animal markets.